A study of nailfold videocapillaroscopy (NVC) in patients with idiopathic inflammatory myopathies (IIMs) finds abnormalities in more than half of patients suggesting this could be a useful clinical tool in diagnosing and managing patients with IIM.
Medpage Today has published the results of their 2018 Rheumatology Specialty Salaray Survey.
Several epidemiological studies have reported that a diagnosis of DM or PM may be associated with increased cancer risk. The association appears stronger for DM than PM.
Lilly has issued an advanced press release on its SPIRIT-H2H trial, wherein ixekizumab (Taltz) was shown to be more effective than than adalimumab (Humira) in a 24 week psoriatic arthritis study.
JAMA Network Open has published that an increasing number of physicians are being excluded from Medicare and other forms of public insurance.
Another injury related to whole body cryotherapy (WBC) has been reported by practitioners in Philadelphia, serving as yet another warning of WBC's potential to cause serious adverse effects.
Dr. Jack Cush reviews the news from the past week on RheumNow.com.
The Dec. 12 issue of the National Vital Statistics Reports from the U.S. Centers for Disease Control and Prevention reports that the most commonly abused drugs causing drug overdose deaths (between 2011-2016) include fentanyl, heroin, oxycodone, and cocaine.
When psoriatic arthritis (PsA) patients become pregnant, they do not have more infertility or adverse pregnancy outcomes compared to healthy controls.
There is a national shortage of a new shingles vaccine, Shingrix, which is a problem for those who want to start the vaccine and those seeking to receive their second and final injection.
Johnson & Johnson has announced the preliminary results of its phase 3 ECLIPSE study; a head-to-head trial wherein guselkumab (Tremfya; an IL-23 inhibitor) was compared to secukinumab (Cosentyx; an IL-17 inhibitor) in adults with moderate to severe plaque psoriasis.
Interactions between disease-related inflammatory processes and the development of several morbidities have been well-studied in RA, particularly heart disease. This is not the case for the often-lethal SSc (estimated standardized mortality ratio between 2.5 and 4.0).
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
